Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Analyst Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MLTX Stock 12 Month Forecast
Average Price Target
$74.00
▲(46.71%Upside)
| Highest Price Target$100.00 | Average Price Target$74.00 | Lowest Price Target$61.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
―
Buy
―
Reiterated
07/30/25
MoonLake Immunotherapeutics: Strategic Leadership Transition and Promising Clinical Progress Drive Buy RatingWe connected with mgmt. for additional color and summarize their comments below. MLTX described the prior CMO departure as an event that was planned well in advance due to personal family reasons, and occurring concurrently with the appointment of new CMO Dr. Wulf Boecher, who was described as much more senior and experienced coming from his prior role as VP Clinical Program head at Galapagos (GLPG, MP, Khurshid). The new CMO will be tasked with assisting in BLA preparations, pharmacovigilance, medical strategy, and future clinical trial plans. MLTX added that the prior CMO was not exposed to any blinded data reviews from VELA, and that the trials continue to run smoothly without any impact from his departure.We note that Dr.
Guggenheim
$80
Buy
58.60%
Upside
Reiterated
07/30/25
LifeSci Capital
$75
Buy
48.69%
Upside
Reiterated
07/29/25
Promising Outlook for MoonLake Immunotherapeutics: Buy Rating Backed by Strong Position in Hidradenitis Suppurativa TreatmentWe recently hosted a KOL dinner to discuss the current treatment landscape/dynamics in hidradenis suppurav a (HS), the clinical potenal of sonelokimab (topline data from the Phase III VELA program expected around September), and the evolving development landscape in the disease. In addi on to following ~1,000 HS paen ts/year, two-thirds of which are moderate-to-severe, the physician parcipa tes in ~90% of the Phase II and III studies in HS. Key takeaways from our discussion include: The KOL prefers to prescribe IL-17 inhibitors over Humira and its biosimilars in HS, but acknowledges that it can be difficult to get Cosen tyx (secukinumab) or Bimz elx (bimekizumab) reimbursed as a first-line treatment opon.
Redburn Atlantic
$65
Hold
28.87%
Upside
Initiated
07/28/25
Needham
$66
Buy
30.85%
Upside
Reiterated
07/23/25
Wedbush
$80
Buy
58.60%
Upside
Reiterated
06/12/25
RBC Capital
$67
Buy
32.83%
Upside
Reiterated
06/03/25
Citi
$72
Buy
42.74%
Upside
Reiterated
06/02/25
H.C. Wainwright
$100
Buy
98.26%
Upside
Reiterated
05/27/25
Wolfe Research
$61
Buy
20.94%
Upside
Upgraded
05/19/25
TD Cowen
―
Buy
―
Reiterated
05/12/25
BTIG
$81→$85
Buy
68.52%
Upside
Reiterated
04/30/25
Stifel Nicolaus
$77
Buy
52.66%
Upside
Reiterated
04/10/25
Cantor Fitzgerald
―
Buy
―
Reiterated
04/04/25
Goldman Sachs
$82→$73
Buy
44.73%
Upside
Reiterated
02/27/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
―
Buy
―
Reiterated
07/30/25
MoonLake Immunotherapeutics: Strategic Leadership Transition and Promising Clinical Progress Drive Buy RatingWe connected with mgmt. for additional color and summarize their comments below. MLTX described the prior CMO departure as an event that was planned well in advance due to personal family reasons, and occurring concurrently with the appointment of new CMO Dr. Wulf Boecher, who was described as much more senior and experienced coming from his prior role as VP Clinical Program head at Galapagos (GLPG, MP, Khurshid). The new CMO will be tasked with assisting in BLA preparations, pharmacovigilance, medical strategy, and future clinical trial plans. MLTX added that the prior CMO was not exposed to any blinded data reviews from VELA, and that the trials continue to run smoothly without any impact from his departure.We note that Dr.
Guggenheim
$80
Buy
58.60%
Upside
Reiterated
07/30/25
LifeSci Capital
$75
Buy
48.69%
Upside
Reiterated
07/29/25
Promising Outlook for MoonLake Immunotherapeutics: Buy Rating Backed by Strong Position in Hidradenitis Suppurativa TreatmentWe recently hosted a KOL dinner to discuss the current treatment landscape/dynamics in hidradenis suppurav a (HS), the clinical potenal of sonelokimab (topline data from the Phase III VELA program expected around September), and the evolving development landscape in the disease. In addi on to following ~1,000 HS paen ts/year, two-thirds of which are moderate-to-severe, the physician parcipa tes in ~90% of the Phase II and III studies in HS. Key takeaways from our discussion include: The KOL prefers to prescribe IL-17 inhibitors over Humira and its biosimilars in HS, but acknowledges that it can be difficult to get Cosen tyx (secukinumab) or Bimz elx (bimekizumab) reimbursed as a first-line treatment opon.
Redburn Atlantic
$65
Hold
28.87%
Upside
Initiated
07/28/25
Needham
$66
Buy
30.85%
Upside
Reiterated
07/23/25
Wedbush
$80
Buy
58.60%
Upside
Reiterated
06/12/25
RBC Capital
$67
Buy
32.83%
Upside
Reiterated
06/03/25
Citi
$72
Buy
42.74%
Upside
Reiterated
06/02/25
H.C. Wainwright
$100
Buy
98.26%
Upside
Reiterated
05/27/25
Wolfe Research
$61
Buy
20.94%
Upside
Upgraded
05/19/25
TD Cowen
―
Buy
―
Reiterated
05/12/25
BTIG
$81→$85
Buy
68.52%
Upside
Reiterated
04/30/25
Stifel Nicolaus
$77
Buy
52.66%
Upside
Reiterated
04/10/25
Cantor Fitzgerald
―
Buy
―
Reiterated
04/04/25
Goldman Sachs
$82→$73
Buy
44.73%
Upside
Reiterated
02/27/25
Best Analysts Covering MoonLake Immunotherapeutics
1 Month
xxx
Success Rate
13/23 ratings generated profit
Average Return
+11.98%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 56.52% of your transactions generating a profit, with an average return of +11.98% per trade.
3 Months
xxx
Success Rate
16/23 ratings generated profit
Average Return
+35.83%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 69.57% of your transactions generating a profit, with an average return of +35.83% per trade.
1 Year
Success Rate
15/23 ratings generated profit
Average Return
+90.45%
reiterated a buy rating 3 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 65.22% of your transactions generating a profit, with an average return of +90.45% per trade.
2 Years
xxx
Success Rate
12/15 ratings generated profit
Average Return
+11.73%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +11.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MLTX Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
14
17
18
19
13
Buy
4
5
4
4
6
Hold
1
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
22
22
23
20
Each month's total comprises the sum of three months' worth of ratings.
MLTX Financial Forecast
MLTX Stock Forecast FAQ
What is MLTX’s average 12-month price target, according to analysts?
Based on analyst ratings, MoonLake Immunotherapeutics’s 12-month average price target is 74.00.
What is MLTX’s upside potential, based on the analysts’ average price target?
MoonLake Immunotherapeutics has 46.71% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MLTX a Buy, Sell or Hold?
MoonLake Immunotherapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
What is MoonLake Immunotherapeutics’s price target?
The average price target for MoonLake Immunotherapeutics is 74.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $61.00. The average price target represents 46.71% Increase from the current price of $50.44.
The highest analyst price target is $100.00 ,the lowest forecast is $61.00. The average price target represents 46.71% Increase from the current price of $50.44.
What do analysts say about MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of MLTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.